



## 2016 Roundtable Series

### Meeting the challenge of antimicrobial resistance: Working together across political, professional and public fronts

---

#### ROUNDTABLE ONE: Wednesday 10 February 2016, The Wellcome Trust, London The economic, societal and human cost of antimicrobial resistance

- 0930 Registration and networking
- 1000 Welcome and overview  
*Dr David Jenkins, Consultant Medical Microbiologist, Lead Infection Control Doctor, and Deputy Director of Infection Prevention and Control University Hospitals of Leicester & Honorary Senior Lecturer, University of Leicester*
- SESSION ONE: Human, health and societal burden of AMR**  
*Chair: Professor Laura Piddock, Director, Antibiotic Action and Professor of Microbiology, University of Birmingham*
- 1005 The macroeconomic impact of antimicrobial resistance  
*Anthony McDonnell, Lead Research Economist, O'Neill Review*
- 1025 Burden of Infectious Diseases in Europe and implications for estimating the burden of AMR  
*Professor Mirjam Kretzschmar, Professor of Dynamics of Infectious Diseases University Medical Centre Utrecht and Chief Science Officer Mathematical Disease Modelling at RIVM*
- 1045 Impact of AMR on the individual patient  
*Professor Céline Pulcini, Professor of Infectious Diseases, University of Lorraine, Nancy, France*
- 1105 COFFEE AND NETWORKING
- SESSION TWO: The impact of AMR on antibiotic R&D**
- 1130 A withering vine or golden opportunity? The changing face of the global research and development landscape  
*Ursula Theuretzbacher, Ph.D. Infectious disease scientist – Anti-infective R&D and clinical practice strategies*
- 1200 The Response of the Pharmaceutical Industry to Antimicrobial Resistance  
*Richard Bax, Senior Partner, Transcrip Partners, Reading*
- 1230 Panel Discussion: Can we really change the AMR burden trajectory?
- 1250 LUNCH AND NETWORKING
- 1350 3 ways to make a difference  
*Dr Mark Toms, Medical Director, Medical Affairs, EUCAN & Ireland for MSD*  
*Sponsored by MSD*
- SESSION THREE –Stemming the tide of resistance through economics, data, alternative therapies and more...**  
*Chair: Ursula Theuretzbacher, Ph.D. Infectious disease scientist – Anti-infective R&D and clinical practice strategies*
- 1410 Big data – the power and importance of accurate surveillance  
*Professor Alan Johnson, Public Health England, London*
- 1430 The role of economic modelling in reducing antimicrobial resistance
- 1450 Industry viewpoint: moving diagnostics to the front of the queue  
*Dr Fred Tenover, Vice President Scientific Affairs, Cepheid & Consulting Professor of Pathology at Stanford University School of Medicine & Adjunct Professor of Epidemiology, Emory University*  
*Sponsored by Cepheid*
- 1510 The potential of alternative therapies to disrupt the rise in resistance  
*Dr Daniel Neill, Institute of Infection and Global Health, University of Liverpool*
- 1530 Panel Discussion - Ideal world: Other than stewardship what are the three key interventions/changes necessary to lever containment or reduction of AMR? Answers to the microphone please ...
- 1550 Closing remarks  
*Professor Laura Piddock, Director, Antibiotic Action and Professor of Microbiology, University of Birmingham*